Success Metrics

Clinical Success Rate
96.9%

Based on 31 completed trials

Completion Rate
97%(31/32)
Active Trials
0(0%)
Results Posted
61%(19 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_3
22
69%
Ph phase_1
4
13%
Ph phase_4
2
6%
Ph phase_2
4
13%

Phase Distribution

4

Early Stage

4

Mid Stage

24

Late Stage

Phase Distribution32 total trials
Phase 1Safety & dosage
4(12.5%)
Phase 2Efficacy & side effects
4(12.5%)
Phase 3Large-scale testing
22(68.8%)
Phase 4Post-market surveillance
2(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

96.9%

31 of 32 finished

Non-Completion Rate

3.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

32

all time

Status Distribution
Completed(31)
Terminated(1)

Detailed Status

Completed31
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
0
Success Rate
96.9%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (12.5%)
Phase 24 (12.5%)
Phase 322 (68.8%)
Phase 42 (6.3%)

Trials by Status

terminated13%
completed3197%

Recent Activity

0 active trials
Showing 5 of 32
completedphase_3

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

NCT03798054
completedphase_4

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

NCT02941367
completedphase_1

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

NCT02803918
completedphase_3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

NCT02749890
completedphase_3

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

NCT02058147
View all 32 trials

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT03798054Phase 3

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Completed
NCT02941367Phase 4

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Completed
NCT02803918Phase 1

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Completed
NCT02749890Phase 3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Completed
NCT02058147Phase 3

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Completed
NCT01798706Phase 3

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

Completed
NCT02274740Phase 2

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Terminated
NCT01768559Phase 3

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Completed
NCT00905255Phase 3

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)

Completed
NCT01147250Phase 3

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Completed
NCT00712673Phase 3

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Completed
NCT00763451Phase 3

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Completed
NCT00713830Phase 3

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

Completed
NCT00688701Phase 3

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy

Completed
NCT00707031Phase 3

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Completed
NCT01175473Phase 2

Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

Completed
NCT00763815Phase 3

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

Completed
NCT00715624Phase 3

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Completed
NCT01517412Phase 3

Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

Completed
NCT01596504Phase 2

Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

Completed

Drug Details

Intervention Type
DRUG
Total Trials
32